MIF and prostate carcinoma: Serum MIF levels were significantly increased, even in this small sample, when we used the milk-diluent based MIF ELISA (our protocol), with non-CaP having 4.18 ± 0.99 ng/ml compared to prostate cancer patients that had 13.06 ± 6.15 ng/ml of MIF in the serum (Fig. 2).